STEM CELL THERAPEUTIC

MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)

MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture method

MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants

MEDIPOST signs a joint research agreement with LG Chemical

MEDIPOST, signs a contract with SK Bioland for an ankle joint indication

MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method’

MEDIPOST acquires the patent in Mexico for ‘CARTISTEM’

MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth promoting composition

MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries

Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year

MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment

MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials